Vitamin D supplementation with standard treatment yielded positive clinical outcomes
in mild and moderate atopic dermatitis; however, the potential benefit of vitamin
D in severe cases remains unclear. This study aimed to evaluate the impact
of vitamin D supplementation on response to standard treatment in pediatrics with
severe atopic dermatitis. The patients were randomized to receive either vitamin D
3 1600 IU/day or placebo, plus baseline therapy of topical 1% hydrocortisone cream
twice daily for 12 weeks. The primary endpoints were the change in mean Eczema
Area and Severity Index (EASI) score at the end of the study and the mean percent
change in EASI score from baseline to week 12. Eighty-six subjects completed the
study. The treated group achieved a significant higher level of 25 hydroxy vitamin
D (P < .001) compared to control group at week 12. The mean EASI score was significantly
lower in the treatment group compared to placebo group (P = .035). The
percent change in EASI score from baseline differed significantly between the supplementation
(56.44 ± 29.33) and placebo (42.09 ± 19.22) groups after intervention
(P = .039). Vitamin D supplementation could be an effective adjuvant treatment that
improves the clinical outcomes in severe atopic dermatitis.